Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SPON2

SPON2

Basics

Aliases:
This biomarker is also known as:
  • FLJ34460,
  • DIL-1,
  • spondin 2,
  • Mindin,
  • spondin 2, extracellular matrix protein,
  • Spondin-2,
  • FLJ22401,
  • FLJ16313,
  • Differentially expressed in cancerous and non-cancerous lung cells 1,
  • DIL1,
  • M-spondin,

View in BioMuta

Description…

SPON2, also known as spondin-2, is a cell adhesion protein that promotes adhesion and outgrowth of hippocampal embryonic neurons. It binds directly to bacteria and their components and functions as an opsonin for macrophage phagocytosis of bacteria. Spondin-2 is essential in the initiation of the innate immune response and represents a unique pattern-recognition molecule in the extacellular matrix for microbial pathogens. Spondin-2 also binds bacterial lipopolysaccharide.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: SPON2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

Spondin-2 has been identified as potential ovarian cancer biomarkers. In a 2007 study (Simon, I. Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8) Spondin 2, B7-H4, and DcR3 were evaluated for their ability to identify clinical disease. The three novel markers and CA125 were elevated in serum of ovarian cancer patients as compared to normal controls.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. SPON2 alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

No associated publications found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.